Age-Related Effects on Nelfinavir and M8 Pharmacokinetics: a Population Study with 182 Children
Open Access
- 1 March 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (3) , 910-916
- https://doi.org/10.1128/aac.50.3.910-916.2006
Abstract
As a relationship between nelfinavir antiretroviral efficacy and plasma concentrations has been previously established, nelfinavir pharmacokinetics was investigated in order to optimize the individual treatment schedule in a pediatric population. A population pharmacokinetic model was developed to describe the concentration-time course of nelfinavir and its active metabolite M8. Individual characteristics were used to explain the large interindividual variability in children. Data from therapeutic drug monitoring in 182 children treated with nelfinavir were analyzed with NONMEM. Then Food and Drug Administration (FDA) current recommendations were evaluated estimating the percentage of children who reached the target minimum plasma concentration (0.8 mg/liter) by using Bayesian estimates. Nelfinavir pharmacokinetics was described by a one- compartment model with linear absorption and elimination. Pharmacokinetic estimates and the corresponding intersubject variabilities for the model were as follows: nelfinavir total clearance, 0.93 liters/h/kg (39%); volume of distribution, 6.9 liters/kg (109%); absorption rate, 0.5 h−1; formation clearance fraction to hydroxy-tert-butylamide (M8), 0.025; M8 elimination rate, 1.88 h−1(49%). Apparent nelfinavir total clearance and volume of distribution decreased as a function of age. M8 elimination rate was increased by concomitant administration of nevirapine or efavirenz. Our data confirm that the FDA recommendations for children from 2 to 13 years are optimal and that the dose recommended for children younger than 2 years is adequate for the children from 2 months to 2 years old. However, in children younger than 2 months, the proposed nelfinavir newborn dose of 40 mg/kg of body weight twice daily is inadequate and we suggest increasing the dose to 50 to 60 mg/kg administered thrice daily. This assumption should be further evaluated.Keywords
This publication has 20 references indexed in Scilit:
- Bayesian Parameter Estimates of Nelfinavir and Its Active Metabolite, Hydroxy-tert-Butylamide, in Infants Perinatally Infected with Human Immunodeficiency Virus Type 1Antimicrobial Agents and Chemotherapy, 2005
- Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1–infected childrenThe Journal of Pediatrics, 2004
- Pharmacokinetics and Pharmacodynamics of Nelfinavir Administered Twice or Thrice Daily to Human Immunodeficiency Virus Type 1-Infected ChildrenClinical Infectious Diseases, 2003
- Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1The Pediatric Infectious Disease Journal, 2003
- High Concentrations of Nelfinavir as an Independent Risk Factor for Lipodystrophy in Human Immunodeficiency Virus-Infected PatientsAntimicrobial Agents and Chemotherapy, 2002
- The Pharmacokinetics of Nelfinavir in HIV-1—Infected ChildrenTherapeutic Drug Monitoring, 2002
- Acetaminophen Developmental Pharmacokinetics in Premature Neonates and InfantsAnesthesiology, 2002
- Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trialThe Lancet, 2002
- Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patientsAIDS, 2001
- Treatment of Human Immunodeficiency Virus 1‐Infected Infants and Children with the Protease Inhibitor Nelfinavir MesylateClinical Infectious Diseases, 1999